Cytokinetics Inc. Stock
Price
Target price
€44.80
€44.80
0.880%
0.4
0.880%
€83.06
31.05.24 / Tradegate
WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cytokinetics Inc. Stock
The Cytokinetics Inc. stock is trending slightly upwards today, with an increase of €0.40 (0.880%) compared to yesterday's price.
With 31 Buy predictions and 2 Sell predictions Cytokinetics Inc. is one of the favorites of our community.
With a target price of 83 € there is a hugely positive potential of 85.27% for Cytokinetics Inc. compared to the current price of 44.8 €.
So far the community has only identified positive things for Cytokinetics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Cytokinetics Inc. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cytokinetics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytokinetics Inc. | 0.880% | 0.448% | -22.087% | 26.554% | -41.438% | 148.889% | - |
| Ardelyx Inc. | 3.070% | 1.608% | 5.441% | 102.500% | 9.308% | 7.085% | - |
| Evolus Inc | - | 0.000% | 7.477% | 37.725% | 27.072% | 32.948% | - |
| Salarius Pharmaceuticals Inc. | - | -3.015% | -6.311% | -66.724% | -30.450% | -98.501% | -99.994% |
Comments
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Truist Financial Co. from $86.00 to $70.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at HC Wainwright from $94.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Barclays PLC from $100.00 to $95.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
